Michael Goldberg is Executive Chairman of Nodality, Inc. During a career spanning 30 years, he has been a company founder, CEO, board member and venture capitalist. Michael joined the life science industry in 1981 and participated in the commercialization of the first generation of recombinant DNA, monoclonal antibody and PCR technology. Michael joined Nodality's board to help guide the commercialization of SCNP (Single Cell Network Profiling) which he thinks has similar disruptive potential for drug development and clinical medicine.

In addition to his work as a corporate board member and investor, Michael has served on the Board of the California Institute for Regenerative Medicine since its inception in 2005 ($3 billion state stem cell agency). Michael is also on the advisory councils of the Harvard Center for Genetics and Genomics, the Stanford Neuroscience Institute, the Caltech Division of Biology, and the Berkeley Center for Law and Technology. He is a member of the Personalized Medicine Coalition and an honorary trustee of the National Childhood Cancer Foundation. Michael is a former board member of the Western Association of Venture Capitalists.

Michael holds a BA from Brandeis University and an MBA from the Stanford Graduate School of Business.

Ms. Brege has over 20 years of executive management experience in the pharmaceutical, biotechnology and venture capital industries. Prior to joining Nodality, Ms. Brege held several senior-level positions at Onyx Pharmaceuticals, Inc., including Executive Vice President and Chief Operating Officer. While at Onyx, she led multiple functions, including commercialization, strategic planning, corporate development, and medical, scientific and government affairs. Prior to Onyx, Ms. Brege was a General Partner at Red Rock Capital Management, a venture capital firm specializing in early stage financing for technology companies.

Previously Ms. Brege was SVP and Chief Financial Officer at COR Therapeutics, helping build the company from an early stage R&D company through commercial launch of a successful cardiovascular product. Earlier in her career, she served as Chief Financial Officer at Flextronics, Inc. and Treasurer of The Cooper Companies. She serves on the Board of Directors of Acadia Pharmaceuticals, Inc., Delcath Systems, Inc. and Pacira Pharmaceuticals, Inc.

Ms. Brege earned her undergraduate degrees from Ohio University (Honors Tutorial College) and her MBA degree from the University of Chicago.

Dr. Nolan received his Ph.D from the Department of Genetics at Stanford at the Herzenberg laboratory, and his B.S. in Genetics from Cornell University, and was a postdoctoral fellow in the laboratory of Dr. David Baltimore at MIT and Rockefeller University. He is the author of over 120 peer-reviewed papers and holds numerous issued patents. He is the recipient of several prestigious awards, and was recently honored as one of the top 25 inventors at Stanford University. He was a Hume Faculty Scholar (1993–98), Trustee of the Leukemia Society of America (1995–98), Burroughs Welcome Fund New Investigator Awardee (1996–2000), HHMI Junior Faculty Scholar Awardee, Leukemia and Lymphoma Society Stohlman Scholar (2000), among others. He is the co-founder of 3 companies, including publicly traded RIGEL (NASDAQ:RIGL).

Mr. Singer is responsible for Maverick's Private Investments globally. He joined Maverick in 2004 from Oscient Pharmaceutical Corporation, where he was Chairman of the Board. Mr. Singer is a founder and former CEO of three healthcare companies: Affymetrix, Inc., Corcept Therapeutics, Inc., and Genesoft Pharmaceuticals, Oscient's predecessor. Mr. Singer currently serves on the boards of several private companies.

In July 2013, Mr. Singer was appointed by the Mayor of San Francisco to be a Health Commissioner and a member of the San Francisco General Hospital Joint Conference Committee.

Mr. Singer received a B.A. from Yale University and an M.B.A. from Stanford University. He was a Crown Fellow of the Aspen Institute, and is currently a Sterling Fellow of Yale University and a director of College Track.

Dr. Gudiksen joined TPG Biotechnology in 2008, with a focus on both healthcare and industrial biotechnology. Prior to joining TPG Biotechnology, Dr. Gudiksen was at McKinsey & Company where he worked on a broad spectrum of strategic topics and M&A opportunities. Prior to this, Dr. Gudiksen received his Ph.D. in chemical physics from Harvard, and his B.S. in chemistry from Stanford. His doctoral work in nanotechnology was recognized with several highly cited publications in leading scientific journals, such as Science and Nature, as well as general audience publications as broad as Scientific American and the Wall Street Journal. Dr. Gudiksen currently serves on the boards of directors of Alphabet Energy, Inc., Auxogyn, Inc. and Nodality, Inc., and is a board observer at DNAnexus, Inc.

Dr. Gregory Critchfield received a Bachelor's Degree in Microbiology with a minor in Chemistry from Brigham Young University in 1976, an MD degree from the University of Utah in 1980, and a master's degree in Biophysical Sciences at the University of Minnesota in 1985. There he also completed fellowships in Clinical Chemistry and in Health Information Sciences sponsored by the National Library of Medicine and boarded in Clinical Pathology. He served as a reviewer and study section chair for the NIH for over 15 years in biomedical computing programs for SBIR, STTR and R01 programs. His research has focused on building quantitative models in many areas of laboratory medicine including anticoagulation control, method standardization, mass spectrometric identification of drugs, predictive value modeling, quantitative health policy analysis and clinical genetics. He has served on the faculty of three medical schools: University of Minnesota, Wayne State University and Duke University. He worked as a practicing clinical pathologist with Intermountain Healthcare for nine years. He then joined Corning Clinical Laboratories in 1995, which became Quest Diagnostics, Inc., where he served as Chief Medical and Science Officer, with responsibility for science, medicine and innovation. He joined Myriad Genetics, Inc. in 1998, where he was President of its diagnostic subsidiary, Myriad Genetic Laboratories, Inc. until March 2010, where he built Myriad Genetic Laboratories, Inc. into one of world's leading molecular diagnostic companies. He chaired the Governor's State Advisory Council on Science and Technology for the state of Utah in 2007. He has served and is serving as an independent director in industry association and various life science companies.

Dr. Snyderman is Chancellor Emeritus at Duke University and James B. Duke Professor of Medicine. He served as Chancellor for Health Affairs and Dean of the School of Medicine from 1989 to 2004. He oversaw the development of the Duke University Health System, one of the most successful integrated health systems in the country and served as its first CEO and President. He was also a prominent researcher in the field of inflammation and has won many awards for his seminal work on leukocyte chemotaxis. In 1987, Dr. Snyderman joined Genentech, Inc. as vice president for medical research and development where he led the development and licensing of important therapeutics and supervised 300 staff members working in pharmacology, clinical research and regulatory affairs. He served on the board of Proctor and Gamble and led its Innovation and Technology Committee. He has been called “the father of personalized medicine” by the Association of American Medical Colleges. Dr. Snyderman has authored nearly 400 manuscripts and numerous books and is a member of the Institute of Medicine and the American Academy of Arts & Sciences.